The survival times of the riluzole group and the control group did not significantly differ in any of the phenotypes (limb-onset ALS, p = 0.890; bulbar-onset ALS, p = 0.788; FAS, p = 0.548; PMA, p = 0.964). This evidence concerns the gene FAS and Onset.